Laboratoires Sérobiologiques, Cognis Care Chemicals’ active ingredients business, has launched Actiwhite LS 9808, a tailor-made whitener meeting market demands for a new generation of skin lighteners.
Actiwhite offers a high capacity to decrease melanogenesis – the process which is responsible for the creation of melanin, which in turn is responsible for the coloration of the human skin. This product property is linked to a decrease of tyrosinase activity in melanocytes and also to an inhibition of melanosome maturation. The dual biological pathway results in a whitening efficacy matching the market benchmark and a visible reduction of skin pigmentation, which has been proven in a clinical test on Asian skin types.
Actiwhite has been developed with components which are known for their excellent skin tolerance, and therefore assure a safe long term use without any irritation to the skin. The whitener can be used in formulations of a wide pH-range and in various lightening care products, anti-age-spots creams, and serums.
Isabelle Benoit, global marketing manager at Laboratoires Sérobiologiques, said: “The skin whitening market is no longer limited to Asian countries, but has become an essential part of the global face and body care market. With Actiwhite, we have developed a highly effective and safe solution, suitable for all market segments.”
Actiwhite LS 9808: Overview of technical data
INCI Name: Water (and) Glycerin (and) Sucrose Dilaurate (and) Polysorbate 20 (and) Pisum Sativum (Pea) Extract
- Preservatives: Phenoxyethanol – Sorbic acid
- Dosage in application: 2.5%
- Solubility: dispersible in water
